Anzeige
Mehr »
Login
Montag, 22.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A11602 | ISIN: NL0010832176 | Ticker-Symbol: 1AE
Tradegate
19.04.24
15:58 Uhr
339,50 Euro
+1,30
+0,38 %
1-Jahres-Chart
ARGENX SE Chart 1 Jahr
5-Tage-Chart
ARGENX SE 5-Tage-Chart
RealtimeGeldBriefZeit
337,70341,4007:50
339,50341,0007:50

Aktuelle News zur ARGENX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoThe Analyst Verdict: argenx In The Eyes Of 12 Experts4
DiWith Vyvgart 'firing' in myasthenia gravis, argenx lays launch plans for next potential autoimmune approval: CEO6
DiARGENX SE - 6-K, Report of foreign issuer3
Diargenx SE: argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease7
10.04.Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy8
27.03.Plans to pursue efgartigimod development in SjD lift argenx shares5
27.03.argenx SE: argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease2
26.03.Key Takeaways From argenx Analyst Ratings7
26.03.Argenx's Vyvgart Approved In Japan For Adults With Primary Immune Thrombocytopenia4
26.03.argenx SE: argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia298VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March...
► Artikel lesen
22.03.Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday3
21.03.Immunovant and Argenx rise as rival Chugai's data fails to impress14
21.03.Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?9
21.03.Argenx, Immunovant Soar - As Tourmaline Bio Plummets - On A Rival's Lackluster Test Results12
21.03.Argenx gains after setback to Roche/Chugai myasthenia gravis therapy38
21.03.ARGENX SE - 20-F, Annual and transition report of foreign private issuers3
21.03.ARGENX SE - 6-K, Report of foreign issuer1
08.03.ARGENX SE - 6-K, Report of foreign issuer4
07.03.argenx SE: argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting719ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term...
► Artikel lesen
07.03.Should You be Confident in Your Investment in argenx SE (ARGX)?10
Seite:  Weiter >>
118 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1